Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors

Patrick F. Smith; Gregory K. Robbins; Robert W. Shafer; Hulin Wu; Song Yu; Martin S. Hirsch; Thomas C. Merigan; Jeong Gun Park; Alan Forrest; Margaret A. Fischl; Gene D. Morse

doi:10.1128/AAC.49.8.3558-3561.2005

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors

Patrick F. Smith, Gregory K. Robbins, Robert W. Shafer, Hulin Wu, Song Yu, Martin S. Hirsch, Thomas C. Merigan, Jeong Gun Park, Alan Forrest, Margaret A. Fischl, Gene D. Morse

Medicine

Research output: Contribution to journal › Article

9 Scopus citations

Abstract

Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.

Original language	English (US)
Pages (from-to)	3558-3561
Number of pages	4
Journal	Antimicrobial agents and chemotherapy
Volume	49
Issue number	8
DOIs	https://doi.org/10.1128/AAC.49.8.3558-3561.2005
State	Published - Aug 1 2005

Fingerprint

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)
Infectious Diseases

Cite this

Smith, P. F., Robbins, G. K., Shafer, R. W., Wu, H., Yu, S., Hirsch, M. S., Merigan, T. C., Park, J. G., Forrest, A., Fischl, M. A., & Morse, G. D. (2005). Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrobial agents and chemotherapy, 49(8), 3558-3561. https://doi.org/10.1128/AAC.49.8.3558-3561.2005

Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. / Smith, Patrick F.; Robbins, Gregory K.; Shafer, Robert W.; Wu, Hulin; Yu, Song; Hirsch, Martin S.; Merigan, Thomas C.; Park, Jeong Gun; Forrest, Alan; Fischl, Margaret A.; Morse, Gene D.

In: Antimicrobial agents and chemotherapy, Vol. 49, No. 8, 01.08.2005, p. 3558-3561.

Research output: Contribution to journal › Article

Smith, PF, Robbins, GK, Shafer, RW, Wu, H, Yu, S, Hirsch, MS, Merigan, TC, Park, JG, Forrest, A, Fischl, MA & Morse, GD 2005, 'Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors', Antimicrobial agents and chemotherapy, vol. 49, no. 8, pp. 3558-3561. https://doi.org/10.1128/AAC.49.8.3558-3561.2005

Smith PF, Robbins GK, Shafer RW, Wu H, Yu S, Hirsch MS et al. Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. Antimicrobial agents and chemotherapy. 2005 Aug 1;49(8):3558-3561. https://doi.org/10.1128/AAC.49.8.3558-3561.2005

Smith, Patrick F. ; Robbins, Gregory K. ; Shafer, Robert W. ; Wu, Hulin ; Yu, Song ; Hirsch, Martin S. ; Merigan, Thomas C. ; Park, Jeong Gun ; Forrest, Alan ; Fischl, Margaret A. ; Morse, Gene D. / Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors. In: Antimicrobial agents and chemotherapy. 2005 ; Vol. 49, No. 8. pp. 3558-3561.

@article{52a44c75391045138da897125d25755f,

title = "Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-na{\"i}ve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors",

abstract = "Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.",

author = "Smith, {Patrick F.} and Robbins, {Gregory K.} and Shafer, {Robert W.} and Hulin Wu and Song Yu and Hirsch, {Martin S.} and Merigan, {Thomas C.} and Park, {Jeong Gun} and Alan Forrest and Fischl, {Margaret A.} and Morse, {Gene D.}",

year = "2005",

month = aug,

day = "1",

doi = "10.1128/AAC.49.8.3558-3561.2005",

language = "English (US)",

volume = "49",

pages = "3558--3561",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "8",

}

TY - JOUR

T1 - Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors

AU - Smith, Patrick F.

AU - Robbins, Gregory K.

AU - Shafer, Robert W.

AU - Wu, Hulin

AU - Yu, Song

AU - Hirsch, Martin S.

AU - Merigan, Thomas C.

AU - Park, Jeong Gun

AU - Forrest, Alan

AU - Fischl, Margaret A.

AU - Morse, Gene D.

PY - 2005/8/1

Y1 - 2005/8/1

N2 - Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.

AB - Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.

UR - http://www.scopus.com/inward/record.url?scp=23044447776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23044447776&partnerID=8YFLogxK

U2 - 10.1128/AAC.49.8.3558-3561.2005

DO - 10.1128/AAC.49.8.3558-3561.2005

M3 - Article

C2 - 16048984

AN - SCOPUS:23044447776

VL - 49

SP - 3558

EP - 3561

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 8

ER -

Access to Document

10.1128/AAC.49.8.3558-3561.2005